Pitfalls of clinical trials on pharmacological treatment for obstructive sleep apnoea: Future directions

Expert Opinion on Investigational Drugs

Volumn 20, Issue 8, 2011, Pages 1033-1037

  Kohler, Malcolm ^a,b   Stradling, John R ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Oxford Centre for Respiratory Medicine   (United Kingdom)

Author keywords

Clinical trials; Continuous positive airway pressure; Drugs; Obstructive sleep apnoea; Treatment

Indexed keywords

ACETAZOLAMIDE; DONEPEZIL; FLUOXETINE; FLUTICASONE; MIRTAZAPINE; NALTREXONE; ONDANSETRON; PAROXETINE; PHOSPHOCHOLINAMIN; PHYSOSTIGMINE; PLACEBO; RESPIRATORY STIMULANT AGENT; SURFACTANT; THEOPHYLLINE; UNCLASSIFIED DRUG; XYLOMETAZOLINE;

CLINICAL EFFECTIVENESS; DIET THERAPY; DISEASE SEVERITY; FUTUROLOGY; HUMAN; OBESITY; PARESTHESIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP APNEA SYNDROME; TEMPOROMANDIBULAR JOINT; TREATMENT OUTCOME; WEIGHT REDUCTION;

AIRWAY RESISTANCE; ANIMALS; CLINICAL TRIALS AS TOPIC; CONTINUOUS POSITIVE AIRWAY PRESSURE; DRUG DISCOVERY; HUMANS; SLEEP APNEA, OBSTRUCTIVE;

EID: 79960348190     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.590473     Document Type: Review

References (39)

1. George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001;56:508-12 (Pubitemid 32588527)
2. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010;7:677-85
3. Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 2003;168:522-30 (Pubitemid 37088593)
4. Kushida CA, Efron B, Guilleminault C. A predictive model for the obstructive sleep apnea syndrome. Ann Intern Med 1997;127:581-7
5. Mezzanotte WS, Tangel DJ, White DP. Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls. Am J Respir Crit Care Med 1996;153:1880-7 (Pubitemid 26187915)
6. Berry RB, McNellis MI, Kouchi K, Light RW. Upper airway anesthesia reduces phasic genioglossus activity during sleep apnea. Am J Respir Crit Care Med 1997;156:127-32 (Pubitemid 27293177)
7. Berry RB, White DP, Roper J, et al. Awake negative pressure reflex response of the genioglossus in OSA patients and normal subjects. J Appl Physiol 2003;94:1875-82 (Pubitemid 36457438)
8. Doherty LS, Nolan P, McNicholas WT. Effects of topical anesthesia on upper airway resistance during wake-sleep transitions. J Appl Physiol 2005;99:549-55 (Pubitemid 41061148)
9. Jenkinson C, Davies RJ, Mullins R, Stradling JR.comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999;353:2100-5 (Pubitemid 29278478)
10. Kohler M, Pepperell JCT, Casadei B, et al. CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J 2008;32:1488-96
11. Kohler M, Smith D, Tippett V, Stradling JR. Predictors of l ong-term compliance with continuous positive airway pressure. Thorax 2010;65:829-32
12. McArdle N, Devereux G, Heidarnejad H, et al. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:1108-14 (Pubitemid 29202543)
13. Bloch KE, Iseli A, Zhang JN, et al. Randomized, controlled trial of two oral appliances for sleep apnea treatment. Am J Respir Crit Care Med 2000;162:246-51 (Pubitemid 30469828)
14. Randerath WJ, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 2011;37:1000-28
15. Tuomilehto HP, Seppa JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009;179:320-7
16. Johansson K, Neovius M, Trolle Lagerros Y, et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ 2009;339:b4609
17. Kohler M, Bloch KE, Stradling JR. Pharmacological approaches to the treatment of obstructive sleep apnoea. Expert Opin Investig Drugs 2009;18:647-56
18. Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999;22:61-7 (Pubitemid 29097899)
19. Prasad B, Radulovacki M, Olopade C, et al. Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep 2010;33:982-9
20. Carley DW, Olopade C, Ruigt GS, Radulovacki M. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007;30:35-41 (Pubitemid 46095381)
21. Hedner J, Kraiczi H, Peker Y, Murphy P. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med 2003;168:1246-51 (Pubitemid 37421845)
22. Moraes W, Poyares D, Sukys-Claudino L, et al. Donezepil improves obstructive sleep apnea in Alzheimer disease. Chest 2008;133:677-83
23. Hedner J, Kraiczi H, Peker Y, Grote L. Reduction of sleep apnea after the orally available cholinesterase inhibitor donezepil. Sleep Med 2005;6:S54-5
24. Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnea: a double-blind evaluation. Chest 1992;101:753-7
25. Hein H, Behnke G, Jorres RA, Magnussen H. The therapeutic effect of theophylline in mild obstructive sleep apnea/hypopnea syndrome: results of repeated measurements with portable recording devices at home. Eur J Med Res 2000;5:391-9
26. Whyte K, Gould G, Airlie A, et al. Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 1988;11:463-72
27. Ferber C, Duclaux R, Mouret J. Naltrexone improves blood gas patterns in obstructive sleep apnoea syndrome through its influence on sleep. J Sleep Res 1993;2:149-55 (Pubitemid 23316814)
28. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50-5 (Pubitemid 38067972)
29. Clarenbach CF, Kohler M, Senn O, et al. Does nasal decongestion improve obstructive sleep apnea? J Sleep Res 2008;17:444-9
30. Jokic R, Klimaszewski A, Mink J, Fitzpatrick MF. Surface tension forces in sleep apnea: the role of a soft tissue lubricant. Am J Respir Crit Care Med 1998;157:1522-5
31. Morrell MJ, Arabi Y, Zahn BR, et al. Effect of surfactant on pharyngeal mechanics in sleeping humans: implications for sleep apnoea. Eur Respir J 2002;20:451-7
32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5
33. Siccoli MM, Pepperell JC, Kohler M, et al. Effects of continuous positive airway pressure on quality of life in patients with moderate to severe obstructive sleep apnea: data from a randomized controlled trial. Sleep 2008;31:1551-8
34. Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-24 (Pubitemid 17131209)
35. Poceta JS, Timms RM, Jeong DU, et al. Maintenance of wakefulness test in obstructive sleep apnea syndrome. Chest 1992;101:893-7
36. Bennett LS, Stradling JR, Davies RJ. A behavioural test to assess daytime sleepiness in obstructive sleep apnoea. J Sleep Res 1997;6:142-5 (Pubitemid 27300273)
37. Eastwood PR, Malhotra A, Palmer LJ, et al. Obstructive sleep apnoea: from pathogenesis to treatment: current controversies and future directions. Respirology 2010;15:587-95
38. Stoewhas AC, Bloch KE, Russi EW, et al. CPAP therapy withdrawal - a model to evaluate treatments for obstructive sleep apnea abstract]. Respiration 2011;82:S8
39. Ryan CF, Lowe AA, Li D, Fleetham JA. Magnetic resonance imaging of the upper airway in obstructive sleep apnea before and after chronic nasal continuous positive airway pressure therapy. Am Rev Respir Dis 1991;144:939-44